FDA Approves Biocon’s Pebrilzo for HER2-Positive Breast Cancer

Biocon secured U.S. Food and Drug Administration approval for Pebrilzo, a pertuzumab biosimilar targeting HER2-positive breast cancer, though commercial rollout is delayed until 2028 under a global patent settlement with reference product maker Genentech, Targeted Onc reported.

In Plain English: The Clinical Takeaway

  • What a biosimilar is: Pebrilzo is a highly similar, highly effective version of an already approved biologic medication (Perjeta), offering the same clinical safety and efficacy profile at potentially lower healthcare costs.
  • The mechanism of action: Pertuzumab binds to the HER2 protein receptor on cancer cells, blocking signaling pathways that drive tumor growth and recruiting immune cells to destroy the malignant tissue.
  • Access timeline: Although approved by regulators, patients will wait until the third quarter of 2028 before the drug reaches the U.S. market due to legal patent agreements.

Showing the Data Behind the Approval

Biocon said that pertuzumab-qcay gained clearance based on an extensive data submission featuring analytical similarity reviews, structural and functional evaluations, and comparative clinical pharmacokinetic metrics. These evaluations demonstrated high similarity to the reference product, with no clinically meaningful differences in quality, safety, efficacy, or immunogenicity, Targeted Onc reported.

Shanghai Henlius’s HLX11 is another pertuzumab biosimilar candidate that has gone through comparative clinical evaluation, with the FDA having accepted its biologics license application in February 2025.

Pertuzumab-qcay is not the first FDA-approved biosimilar to Perjeta. On November 13, 2025, the FDA approved pertuzumab-dpzb as the first biosimilar to the reference product and designated it as interchangeable, allowing pharmacy-level substitution subject to applicable state laws.

Global Patent Settlements and Launch Timelines

Despite having obtained FDA clearance, the rollout of pertuzumab-qcay across the United States by Biocon remains contingent upon the conditions outlined in its worldwide settlement and licensing contract with Genentech. Announced on October 14, 2026, the agreement resolved pending disputes between the companies across the United States, Canada, and other jurisdictions, Targeted Onc reported.

Under the agreement, Biocon identified the third quarter of calendar year 2028 as the earliest licensed U.S. launch date for Pebrilzo. Pending regulatory greenlights, the company also pointed to the first quarter of 2027 as the earliest window when marketing could begin in the United Kingdom and the European Union.

In September 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use delivered a favorable recommendation favoring marketing authorization for Biocon’s pertuzumab biosimilar—presented as a 420-mg/14-mL concentrate for infusion—to treat HER2-positive breast cancer across various stages of the condition.

Biosimilar Candidate Developer Regulatory Milestone Status / Timeline
Pertuzumab-dpzb (Poherdy) Industry Sponsor FDA Approval Approved as interchangeable (November 2025)
HLX11 Shanghai Henlius BLA Acceptance Accepted by FDA (February 2025)
Pebrilzo (Pertuzumab-qcay) Biocon Limited FDA Approval / Settlement U.S. launch slated for Q3 2028

Expanding the Global Oncology Portfolio

Pebrilzo expands Biocon’s oncology portfolio into major HER2-directed therapies. The company is also developing proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, extending its pipeline across HER2-directed treatment and immuno-oncology.

“The U.S. FDA approval of Pebrilzo, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars,” Shreehas Tambe, CEO and managing director of Biocon Limited, told Targeted Onc in the company’s news release.

Contraindications & When to Consult a Doctor

HER2-positive breast cancer therapies carry specific clinical considerations and contraindications. Patients with a known hypersensitivity to pertuzumab or any of its excipients must avoid administration. Because HER2-targeted therapies can cause left ventricular dysfunction and embryo-fetal toxicity, baseline cardiac function assessments—such as an echocardiogram or MUGA scan—are mandatory before initiating treatment.

Patients experiencing symptoms such as shortness of breath, new or worsening cough, swelling of the extremities, or sudden fatigue during their therapeutic regimen must contact their oncology care team immediately for cardiac evaluation.

Future Trajectory for Biosimilar Access

Biocon said that European market introduction is targeted for early 2027, pending final European Commission authorization following the September 2026 CHMP positive opinion.

References

  • Biocon gets U.S. FDA approval for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, expanding its oncology portfolio. News release. Biocon Limited. November 16, 2026.
  • Biocon secures earliest licensed launch dates for Pebrilzo (bPertuzumab) following global patent settlement with Genentech. News release. Biocon Limited. October 14, 2026.
  • Breast cancer HER2 status. American Cancer Society.
  • Key statistics for breast cancer. American Cancer Society.
  • FDA approves new interchangeable biosimilar to Perjeta. US FDA. November 13, 2025.

Always consult a qualified healthcare professional regarding any medical condition or therapeutic regimen.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

San Jose Sea Lions Unveil 2026-27 Unity Games Schedule